301089 Stock Overview
Engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Tuoxin Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.89 |
| 52 Week High | CN¥62.00 |
| 52 Week Low | CN¥25.95 |
| Beta | -0.96 |
| 11 Month Change | 19.98% |
| 3 Month Change | 18.67% |
| 1 Year Change | -35.88% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301089 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 14.1% | 9.8% | 9.9% |
| 1Y | -35.9% | -1.6% | 1.2% |
Return vs Industry: 301089 underperformed the CN Pharmaceuticals industry which returned -1.6% over the past year.
Return vs Market: 301089 underperformed the CN Market which returned 1.2% over the past year.
Price Volatility
| 301089 volatility | |
|---|---|
| 301089 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 4.5% |
Stable Share Price: 301089's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301089's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,550 | Shaohua Yang | www.tuoxinpharm.com |
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research, development, production, and sale of chemical synthesis, biological fermentation nucleoside (acid) APIs, and pharmaceutical intermediates in China and internationally. It offers purine base, pyrimidine base, nucleosides, nucleotide, deoxynucleosides, dehyfrated nucleoside, 2'-modified, Cybinucleoside, and sugar series, and Azvudine intermediate.
Tuoxin Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 301089 fundamental statistics | |
|---|---|
| Market cap | CN¥4.42b |
| Earnings (TTM) | -CN¥68.24m |
| Revenue (TTM) | CN¥397.29m |
11.1x
P/S Ratio-64.7x
P/E RatioIs 301089 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301089 income statement (TTM) | |
|---|---|
| Revenue | CN¥397.29m |
| Cost of Revenue | CN¥364.66m |
| Gross Profit | CN¥32.63m |
| Other Expenses | CN¥100.87m |
| Earnings | -CN¥68.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 26, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 8.21% |
| Net Profit Margin | -17.18% |
| Debt/Equity Ratio | 0% |
How did 301089 perform over the long term?
See historical performance and comparison